Pre-treatment with bryostatin or lonafirnib improves the efficacy of imatinib against G0/G1 cells in the Ph+ cell line K562

T L Holyoake, E K Allan, J C Mountford, L Richmond, S J Harrison, M A Elliott, H G Jorgensen

Research output: Contribution to journalConference Contribution

Abstract

Meeting abstract 2420 looks at pre-treatment with bryostatin or lonafirnib improves the efficacy of imatinib against G0/G1 cells in the Ph+ cell line, K562.
Original languageEnglish
Article number2420
Pages (from-to)654A-654A
Number of pages1
JournalBlood
Volume102
Issue number11
Publication statusPublished - 16 Nov 2003
Event45th Annual Meeting of the American-Society-of-Hematology - San Diego, United States
Duration: 6 Dec 20039 Dec 2003

Keywords

  • pre-treatment
  • bryostatin
  • lonafirnib
  • efficacy
  • imatinib
  • G0/G1
  • ph+ cell line

Fingerprint Dive into the research topics of 'Pre-treatment with bryostatin or lonafirnib improves the efficacy of imatinib against G0/G1 cells in the Ph+ cell line K562'. Together they form a unique fingerprint.

  • Cite this

    Holyoake, T. L., Allan, E. K., Mountford, J. C., Richmond, L., Harrison, S. J., Elliott, M. A., & Jorgensen, H. G. (2003). Pre-treatment with bryostatin or lonafirnib improves the efficacy of imatinib against G0/G1 cells in the Ph+ cell line K562. Blood, 102(11), 654A-654A. [2420].